Medtronic News

Medtronic Launches New Solutions to Help Monitor Patients for COVID-19

New Offerings Available to Existing Medtronic Care Management Services Customers as well as New Hospital Systems, Health Plans and Employers

DUBLIN, March 27, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced its Medtronic Care Management Services (MCMS) business is launching two new solutions designed to help assess, monitor, and triage support for patients who may be concerned about COVID-19 and their respiratory symptoms. It has already launched its new Respiratory Infectious Disease Health Check to existing MCMS customers, and it is now launching a new COVID-19 Virtual Care Evaluation and Monitoring solution available to U.S. health systems, health plans and employers.

“With the rapid spread of COVID-19, we know that alternative approaches to screening, disease monitoring, and patient education are urgently needed to reduce additional population exposure to the virus and ease the burden on health care providers and facilities. It’s easy to understand why staying in self-quarantine and monitoring your own symptoms is challenging. Unless you consult a medical professional, it’s hard to know when your symptoms warrant seeking medical care,” said Sheri Dodd, vice president and general manager of MCMS. “Using technology for self-reported symptom monitoring may play an important role in slowing the spread of the disease and helping escalate patient needs to their provider when appropriate.”

The Respiratory Infectious Disease Health Check for existing MCMS customers is an included add-on to all current care management programs. The Respiratory Infectious Disease Health Check helps patients with chronic, co-morbid health conditions who are at the highest risk for complications or mortality associated with COVID-19 track their respiratory infectious disease symptoms and body temperature through daily health checks. The program reacts dynamically during the health check to present symptom questions based on the patient’s previous responses, and provides patient education to encourage and support self-care. Data is aggregated for clinician review and action if additional intervention is needed.

For health systems, health plans and other employers new to MCMS programs, the company is launching a stand-alone assessment and monitoring service. The COVID-19 Virtual Care Evaluation and Monitoring solution uses a virtual assistant to evaluate patients through a Centers for Disease Control and Prevention (CDC) guideline-based survey for COVID-19 symptoms. If the user’s symptoms warrant it, the solution connects them to the MCMS nurse command center, where registered nurses review the patient’s data and either identify recommendations or the need for additional care assessment, based on the CDC guidelines. This could include a recommendation to continue monitoring symptoms at home, or to contact a healthcare provider directly.

“True to the Medtronic Mission, the health and safety of our customers, their patients, and our employees remains our highest priority as we address this unprecedented outbreak,” says John Liddicoat, M.D., executive vice president and president, Medtronic Americas Region. “Around the world, we are in ongoing communication with customers, suppliers, and governments to prioritize needs to the best of our ability. These solutions aim to help manage unnecessary exposures, minimize burden on the health care system, and escalate the most seriously ill patients for immediate care.”

About Medtronic Care Management Services (MCMS)

Medtronic Care Management Services (www.medtronic.com/caremanagementservices) offers remote patient monitoring that uses a combination of care management services, patient engagement solutions, and data analytics and reporting. MCMS helps health plans, ACOs, IDNs, and home health agencies focus their care on at-risk patients with actionable insights. The business’ remote patient monitoring solutions are designed to scale and integrated into customers’ population health and care management efforts – covering the diverse needs of patients with complex, chronic, co-morbid health conditions.

About Medtronic

Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take health care Further, Together.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to the launch and market acceptance of new solutions, the impact of COVID-19 on our business or operations, competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation and general economic conditions and other risks and uncertainties described in the Company's periodic reports on file with the U.S. Securities and Exchange Commission including the most recent Annual Report on Form 10-K of the Company, as filed with the U.S. Securities and Exchange Commission. In some cases, you can identify these statements by forward-looking words, such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "looking ahead," "may," "plan," "possible," "potential," "project," "should," "will," and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. Medtronic does not undertakes to update its forward-looking statements or any of the information contained in this press release, including to reflect future events or circumstances.

-end-

Laura Griffith
Public Relations
+1-763-505-5598

Ryan Weispfenning
Investor Relations
+1-763-505-4626
